Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Events

News

News

  • Press Releases
  • Presentations
  • Events

Special Meeting of Shareholders

Mar 31, 2026 • 11:00 am EST
Letter of Transmittal
PDF
Definitive Proxy Statement
PDF
Proxy
PDF
Voting Instruction Form
PDF
Audio
Webcast
© 2026 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences